ImmunityBio, Inc.
IBRX
$2.51
$0.041.62%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 29.09% | -28.33% | -26.25% | -39.73% | -40.00% |
| Total Depreciation and Amortization | -5.18% | -6.23% | -5.13% | -2.47% | 1.38% |
| Total Amortization of Deferred Charges | -46.72% | -46.68% | -23.90% | 32.65% | 160.39% |
| Total Other Non-Cash Items | -98.94% | 481.65% | 306.87% | 586.78% | 188.58% |
| Change in Net Operating Assets | -588.36% | -248.38% | -183.38% | -374.30% | 149.71% |
| Cash from Operations | -6.67% | -23.13% | -22.24% | -12.26% | -8.67% |
| Capital Expenditure | 77.48% | 69.36% | 69.87% | 60.47% | 60.87% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -4,800.00% | 29.38% | -678.59% | -123.20% | -99.89% |
| Cash from Investing | 59.81% | 61.58% | -170.51% | -165.37% | -211.62% |
| Total Debt Issued | -78.52% | -6.07% | 67.55% | 106.70% | 159.28% |
| Total Debt Repaid | 16.88% | -12.00% | 15.63% | -2.60% | -32.76% |
| Issuance of Common Stock | 72.29% | -43.13% | -4.59% | -28.51% | 82.47% |
| Repurchase of Common Stock | -58.73% | -196.38% | -1,043.81% | -1,056.91% | -458.93% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 28,700.59% | 99.12% | -- |
| Cash from Financing | -49.56% | -19.78% | 68.58% | 58.20% | 139.00% |
| Foreign Exchange rate Adjustments | 92.12% | 58.65% | 8.33% | -137.56% | -202.82% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -175.78% | -189.41% | 570.85% | -14.70% | 310.73% |